ATE555212T1 - Verfahren und zusammensetzungen zur identifizierung von prostatakrebs oder einer humoralen immunantwort gegen prostatakrebs - Google Patents

Verfahren und zusammensetzungen zur identifizierung von prostatakrebs oder einer humoralen immunantwort gegen prostatakrebs

Info

Publication number
ATE555212T1
ATE555212T1 AT08726345T AT08726345T ATE555212T1 AT E555212 T1 ATE555212 T1 AT E555212T1 AT 08726345 T AT08726345 T AT 08726345T AT 08726345 T AT08726345 T AT 08726345T AT E555212 T1 ATE555212 T1 AT E555212T1
Authority
AT
Austria
Prior art keywords
prostate cancer
immune response
compositions
methods
markers
Prior art date
Application number
AT08726345T
Other languages
English (en)
Inventor
Karin Jooss
Thomas Harding
Minh Nguyen
Kathryn Koprivnikar
Original Assignee
Biosante Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biosante Pharmaceuticals Inc filed Critical Biosante Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE555212T1 publication Critical patent/ATE555212T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/53—Colony-stimulating factor [CSF]
    • G01N2333/535—Granulocyte CSF; Granulocyte-macrophage CSF

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT08726345T 2007-03-02 2008-03-03 Verfahren und zusammensetzungen zur identifizierung von prostatakrebs oder einer humoralen immunantwort gegen prostatakrebs ATE555212T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90468807P 2007-03-02 2007-03-02
US97802907P 2007-10-05 2007-10-05
PCT/US2008/002788 WO2008109030A2 (en) 2007-03-02 2008-03-03 Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer

Publications (1)

Publication Number Publication Date
ATE555212T1 true ATE555212T1 (de) 2012-05-15

Family

ID=39738974

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08726345T ATE555212T1 (de) 2007-03-02 2008-03-03 Verfahren und zusammensetzungen zur identifizierung von prostatakrebs oder einer humoralen immunantwort gegen prostatakrebs

Country Status (6)

Country Link
US (1) US7939271B2 (de)
EP (1) EP2132324B1 (de)
JP (1) JP5247729B2 (de)
AT (1) ATE555212T1 (de)
CA (1) CA2679664C (de)
WO (1) WO2008109030A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110038801A1 (en) * 2007-12-21 2011-02-17 Biosante Pharmaceuticals, Inc. Methods and compositions for identifying lung cancer or a humoral immune response against lung cancer
US8840881B2 (en) 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
CA2877721A1 (en) * 2012-06-27 2014-01-03 Berg Llc Use of markers in the diagnosis and treatment of prostate cancer
US10746735B2 (en) 2014-02-10 2020-08-18 Oncimmune Germany Gmbh Marker sequences for diagnosing and stratifying SLE patients
WO2018234577A1 (en) * 2017-06-23 2018-12-27 Protagen Ag IMMUNO-ONCOLOGY FOR THE TREATMENT OF CANCER
ES2908885T3 (es) * 2017-07-05 2022-05-04 Vcc Medical Deutschland Gmbh Método para fabricar una vacuna tumoral
EP4204813A4 (de) * 2020-08-28 2024-11-27 The Johns Hopkins University Harnglycoproteine zur frühen erkennung und behandlung von aggressivem prostatakrebs
CH719837B1 (de) * 2021-04-28 2025-03-31 Kansai Medical Univ Educational Corporation Verfahren zum nachweis einer oralen neoplastischen läsion, testreagenz und testkit

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5904920A (en) 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US6033674A (en) 1995-12-28 2000-03-07 Johns Hopkins University School Of Medicine Method of treating cancer with a tumor cell line having modified cytokine expression
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
CA2318372C (en) 1998-02-02 2008-08-19 Johns Hopkins University School Of Medicine A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
CA2349217C (en) 1998-11-03 2012-07-31 Johns Hopkins University Cancer-associated antigens and methods of their identification
AU5458500A (en) 1999-06-02 2000-12-18 Cell Genesys, Inc. Regulation of systemic immune responses utilizing cytokines and antigens
AU2002222610A1 (en) * 2000-12-13 2002-06-24 Sumitomo Pharmaceuticals Company, Limited Transgenic animal expressing hla-a24 and utilization thereof
WO2003106682A1 (ja) * 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
US20060057127A1 (en) * 2004-09-10 2006-03-16 Pocheng Liu Cytokine-expressing cellular vaccines for treatment of prostate cancer

Also Published As

Publication number Publication date
US20080279831A1 (en) 2008-11-13
US7939271B2 (en) 2011-05-10
JP2010520453A (ja) 2010-06-10
CA2679664C (en) 2017-04-25
EP2132324B1 (de) 2012-04-25
EP2132324A4 (de) 2010-03-17
WO2008109030A2 (en) 2008-09-12
WO2008109030A3 (en) 2008-10-30
EP2132324A2 (de) 2009-12-16
CA2679664A1 (en) 2008-09-12
JP5247729B2 (ja) 2013-07-24

Similar Documents

Publication Publication Date Title
EP2385062A3 (de) Verfahren und Zusammensetzungen zur Behandlung von Prostatakrebs oder zur Induktion einer humoralen Immunreaktion gegen Prostatakrebs
CY1121136T1 (el) Φυτικα εκχυλισματα που περιεχουν κανναβινοειδη ως νευροπροστατευτικους παραγοντες
IL291633A (en) Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
CY1120102T1 (el) Συνθεσεις και μεθοδοι για μειωση τριγλυκεριδιων χωρις αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
ECSP10010697A (es) Inhibidores de dpp-iv para uso en el tratamiento de nafld
CL2008002782A1 (es) Anticuerpo anti-bv8 neutralizante; composicion que lo comprende; y su uso para tratar tumores en humanos previamente tratados con un antagonista del factor de crecimiento endotelial vascular.
EA200901144A1 (ru) Ингибиторы киназы pim и способы их применения
MX2014003832A (es) Molecula de union al antigeno que induce la inmunorespuesta al antigeno objetivo.
AR084831A1 (es) Terapia anticancer mediante inhibidores de quinasa
BR112015012295A8 (pt) Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
MX373965B (es) Composiciones de inhibidores de c1 esterasa para usarse en el tratamiento, inhibición, o prevención de angioedema hereditario (hae).
IN2012DN03883A (de)
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
PL2202470T3 (pl) Sposób i system wykorzystywania energii odnawialnych
AR080872A1 (es) Biomarcadores para inhibidores de mdm2 para su uso en el tratamiento de enfermedad
PH12019502710A1 (en) Fgfr2 inhibitors for the treatment of cholangiocarcinoma
MX386750B (es) MARCADORES DE METILACIÓN Y DE miARN PARA LA DETECCIÓN DE CÁNCER.
NZ601065A (en) Wnt antagonists and methods of treatment and screening
EA201200118A1 (ru) Дифференцировка мезенхемальных стволовых клеток
MX2010005395A (es) Metodo para tratar artritis.
ATE533838T1 (de) Verfahren zur verbesserten einführung von dna in bakterienzellen
WO2012073047A3 (en) Compositions and methods
WO2013086260A3 (en) Combination therapy for treatment of cancer
EP4524569A3 (de) Verfahren, zusammensetzungen und vorrichtungen zur behandlung von krebs mit illudofulvenen
WO2008109030A3 (en) Methods and compositions for identifying prostate cancer or a humoral immune response against prostate cancer